Hemoglobin, hematocrit and total red blood cell volume
| . | Pre . | Days of rhEpo treatment . | |||||
|---|---|---|---|---|---|---|---|
| 0 . | 2 . | 4 . | 6 . | 10 . | 14 . | 28 . | |
| Hemoglobin (g.L−1) | 143 ± 6 | 142 ± 6 | 144 ± 4 | 145 ± 7 | 150 ± 8* | 150 ± 7* | 153 ± 11* |
| Hematocrit (%) | 43.9 ± 1.8 | 43.5 ± 1.8 | 44.3 ± 1.4 | 44.5 ± 2.2 | 45.9 ± 2.3* | 46.1 ± 2.2* | 46.8 ± 3.5* |
| RBCV (mL) | 2825 ± 295 | 2854 ± 316 | 2861 ± 366 | 2908 ± 362 | 2917 ± 407 | 3072 ± 343* | 3109 ± 441* |
| . | Pre . | Days of rhEpo treatment . | |||||
|---|---|---|---|---|---|---|---|
| 0 . | 2 . | 4 . | 6 . | 10 . | 14 . | 28 . | |
| Hemoglobin (g.L−1) | 143 ± 6 | 142 ± 6 | 144 ± 4 | 145 ± 7 | 150 ± 8* | 150 ± 7* | 153 ± 11* |
| Hematocrit (%) | 43.9 ± 1.8 | 43.5 ± 1.8 | 44.3 ± 1.4 | 44.5 ± 2.2 | 45.9 ± 2.3* | 46.1 ± 2.2* | 46.8 ± 3.5* |
| RBCV (mL) | 2825 ± 295 | 2854 ± 316 | 2861 ± 366 | 2908 ± 362 | 2917 ± 407 | 3072 ± 343* | 3109 ± 441* |
Mean values (± SD) for 8 participants. Venous blood samples and total red blood cell volume (RBCV; determined by means of a carbon monoxide rebreathing technique) were obtained before (Pre) and on several occasions during treatment with recombinant human Epo (rhEpo). The statistical differences from pre-rhEpo values were calculated using the Wilcoxon test.
P < .05.